




Philip Cohen trained at University
College London and, after
postdoctoral research at the
University of Washington, joined
the University of Dundee Scotland,
in 1971, where he has worked ever
since. He is a Royal Society
Research Professor and Director
of the Medical Research Council
Protein Phosphorylation Unit. His
main contributions have been in
the area of protein
phosphorylation and its role in cell
regulation and human disease. In
1998, he was knighted for his
contributions to biochemistry and
the development of Life Sciences
at Dundee.
What turned you on to biology
in the first place? I have always
had a great love of natural history,
especially ornithology, and still
keep a telescope in my house that
is permanently trained over the
estuary of the river Tay, which lies
at the bottom of my garden. I
naively imagined that biochemistry
might be a blend of chemistry and
natural history. The reality turned
out to be quite different and I only
became turned on to research
near the end of my undergraduate
degree, after carrying out a short
research project on haemoglobin
structure with Michael Rosemeyer,
whose laboratory I then joined as a
graduate student.
Do you have a favourite paper?
If really pushed, it would have to
be Earl Sutherland’s discovery of
the first ‘second messenger’ cyclic
AMP (Rall, T.W. et al. (1957). J.
Biol. Chem. 224, 463-475). How
hormones exert their effects on
cells was a total mystery before
Sutherland’s demonstration that
adrenergic stimulation of glycogen
phosphorylase activity could be
reproduced in liver homogenate.
I keep stumbling across proteins
that are controlled by
ubiquitination, which has raised
my awareness of the original
discovery of the role of ubiquitin in
protein turnover (Ciechanover et
al., 1978, Biochem. Biophys. Res.
Commun. 81, 1100-1105). This
paper provided a totally
unexpected explanation to a
problem that had defied solution
for many years, and is a close
runner up.
I recently published my ‘top five’
papers in The Scientist (Vol 18, 28):
none of the five I chose had been
published in ‘high impact’ journals.
Really interesting papers are
widely read and highly cited
irrespective of where they are
published. 
Do you have a scientific hero?
Yes: Carl Cori, a great scientist
and a wonderful person. His
laboratory at Washington
University, St Louis, trained almost
the entire post-war generation of
American biochemists in the
1940s, 50s and 60s. Many future
Nobel Laureates spent their
formative years in his laboratory,
including Earl Sutherland, Edwin
Krebs, Arthur Kornberg and
Severo Ochoa. Carl and his wife
Gerti themselves won the 1947
Nobel Prize for Medicine or
Physiology for their work on
glycogen metabolism. 
In 1975 I received my first
invitation to talk at a Gordon
Conference in New Hampshire and
wrote to Carl (who had by then
‘retired’ to the Massachusetts
General Hospital) asking whether
he could spare me a few minutes
to talk about the early days in
glycogen metabolism, for a book I
was writing. To my great
astonishment I received an
enthusiastic response inviting me
to lunch at his house! In an
inspiring meeting he told me
everything about his life in science,
including how he had persuaded a
shoe manufacturer in St Louis by
the name of Sigma to sell ATP, its
first scientific product! In 1983,
aged 82, Carl visited Dundee,
where he gave two memorable
lectures, a historical one about the
Life and Work of Earl Sutherland
and another about his latest
research on the genetics of
glucose-6-phosphatase.
What is your favourite
conference? The first one I ever
attended, as a first year graduate
student. It was a protein chemistry
Summer School held in a
monastery on the Island of St
Georgio, just across the water
from St Mark’s Square in Venice. It
was there that I first met my future
postdoctoral mentor Edmond
Fischer. A vivid memory was
hearing Howard Schachman’s
hilarious lecture on ‘The Academic
Pathway’ which had me ‘in
stitches.’ A framed picture of the
conference participants still has
pride of place in my office.
What has been your biggest
mistake in research? A paper I
published in 1982 claiming that
many aminoacyl tRNA synthetases
were regulated by reversible
phosphorylation. At the time, only
a handful of proteins had been
identified that were regulated by
reversible phosphorylation and I
thought that I had at least doubled
the number in one go! We had
found that many tRNA synthetases
became inactivated upon
incubation with MgATP and
another protein factor, which I
thought was a protein kinase.
Inactivation was stable to gel-
filtration and reversed by another
protein factor which, like protein
phosphatases, was inhibited by
sodium fluoride (Damuni, Z. et al.,
(1982). Eur. J. Biochem. 129, 57-
65). Several years later we realised
that the inactivating factor was
one or more enzymes that
converted ATP to inorganic
pyrophosphate, a product of the
tRNA synthetase reaction and a
potent inhibitor of these enzymes.
The reactivating factor was one or
more inorganic pyrophosphatases
which, like protein phosphatases,
are also inhibited by fluoride. Our
mistake was to publish before we
had established whether
inactivation and reactivation was
actually accompanied by the
phosphorylation and
dephosphorylation of these
enzymes. No-one is infallible and
in the course of a long career, one
is bound to make occasional
mistakes. What is important is that
the experimental data are correct
and that mistakes are clearly and
publicly retracted, once one is
really sure that they are wrong. A
note explaining our error was
published a few years later
(Schelling et al., 1986, Biochem.
Soc. Trans. 15, 271-272).
What is the best advice you’ve
been given? Ed Fischer taught
me that, although it is important to
do sound and thorough work, it is
the biological significance of the
problem that is paramount. If you
overdo the fine detail, you may
end up losing so much time that
you never crack the big problem.
Don’t lose sight of the big picture.
In Summer 1971, I returned to
the UK to decide which job to
accept. I had thought I might take
a second postdoctoral fellowship
at the MRC Laboratory of
Molecular Biology (LMB) in
Cambridge, but Brian Hartley at
LMB dissuaded me: his advice
was that I should accept a
university faculty appointment
right away, if I had an interesting
research problem I wanted to
solve, so I accepted a lecturership
in biochemistry at Dundee at the
tender age of 26, a decision I have
never regretted. It concerns me
that today so many scientists do
not start their independent
scientific careers until their mid-
thirties or even later. One needs as
many years as possible when
energy levels are at their highest
and before short-term memory
problems start to impair instant
recall!
Some time arriving at Dundee,
Max Perutz invited me to give a
seminar at LMB. On receiving the
title of my talk, he replied telling
me that it was too boring and
advising me to come up with
something more interesting if I
wanted a decent-sized audience!
Advice I have tried to follow ever
since.
Any strong views on journals
and the peer review system?
The emphasis that many
scientists, universities, research
institutes and funding agencies
place on getting their papers
published in so-called ‘high
impact’ journals has got
completely out of proportion and
is the worst development in
science over the past 15 years.
Many weak papers are published
in these journals because, like
tabloid newspapers, they are
frequently more interested in the
sensational than the sound.
The evaluation of papers based
on where they are published,
rather than on their content, has
come about because biology has
become so vast that fewer and
fewer people attempt to keep up
with the literature and we have all
become so busy that we are
attracted by simple solutions that
avoid the need for thorough and
critical assessment. My own view
is that, if one is going to resort to
this, evaluation by the number of
citations a paper has garnered is
a better guide to its usefulness,
although this also has limitations.
For example, the larger the field,
the more citations a paper is
likely to receive, and really
ground-breaking work may not be
widely cited if it is too far ahead
of its time.
I suppose I am the living proof
that publishing in ‘high impact’
journals does not matter. I have
nearly always supported
European journals and frequently
published some of my best work
in relatively new journals without
established reputation (including
Current Biology in its early days)
to try and help them succeed. But
despite having published only one
paper in Cell and only two in
Nature over the past 30 years,
according to the Institute for
Scientific Information, I was the
2nd most cited scientist in the
world between January 1992 and
February 2003 in the field of
biology and biochemistry.
What is your great ambition in
research? From 1973–1997 my





protein kinase 1 (PDK1), finally
filled in the key ‘missing link’ in the
chain of events ‘downstream of
phosphatidylinositol (3,4,5)
trisphosphate (Alessi et al. (1997).
Curr. Biol. 7, 261-269). There are
many details still to be filled in
and, for sure, a few surprises still
in store, but I believe that the
outlines are now clear.
Currently, I am trying to
understand the signaling pathways
that become activated in immune
cells following pathogenic
infection, and which trigger the
production of proinflammatory
cytokines and inflammatory
mediators. This is a really
important area that may eventually
lead to the development of
improved drugs to treat chronic
inflammatory diseases, like
rheumatoid arthritis and psoriasis.
So my greatest ambition right now
is to make a major breakthrough
that will help to solve this complex
problem before I am supposed to
‘retire’ in 2012!
What are the big questions to
be answered next in your field?
I think that history will show that
the 1980s and1990s was the
golden era of signal transduction.
One of the major outstanding
problems is how signal integration
is achieved. The myriad
interconnections and feedback
loops, which vary from cell to cell
and signal to signal, are of mind-
boggling complexity, but crucial
to understanding the system and
identifying promising drug targets.
A huge amount of work needs to
be done to identify all the
physiological targets of protein
kinases and phosphatases and
how reversible phosphorylation
regulates their function. There is
still insufficient quantitative
information about the molar
concentrations of components of
signalling pathways, the
stoichiometries of
phosphorylation and the rate
constants of individual processes
under physiological conditions.
Until much more quantitative
information becomes available, I
doubt whether mathematical
modelling of these processes is
going to get us very far.
What other issues about the
conduct of science concern
you? I have never been more
worried about the increasing
pervasive bureaucracy. that is in
danger of stifling scientific
research. Recently, I was made to
attend a course on how to recruit
staff, although I have recruited
literally hundreds of team leaders,
postdoctoral fellows and graduate
students over the past 30 years,
and my track record in this area is
not all that bad!
MRC Protein Phosphorylation Unit,
University of Dundee, Dow Street,
Dundee DD1 5EH, Scotland. 
E-mail: p.cohen@dundee.ac.uk
Current Biology Vol 14 No 15
R598
